Skip to main content
Premium Trial:

Request an Annual Quote

Orchid and Genetic Technologies Exchange Licenses

NEW YORK, May 30 -- Orchid BioSciences and Genetic Technologies have licensed each other's technologies, the companies said today.

 

Genetic Technologies, based in Melbourne, Australia, obtains exclusive licenses to Orchid's SNP panels for paternity and forensic DNA testing services, as well as to Orchid's Elucigene diagnostic kits, for the areas of Australia, New Zealand, and Southeast Asia. Moreover, it acquires a non-exclusive license to primer extension patents held by Orchid.

 

In return, Orchid will receive royalties from revenues that Genetic Technologies will generate using these technologies. Orchid, located in Princeton, NJ, also receives an option to license Genetic Technologies' non-coding patents for SNP analysis, as well as clearance for past business activities that may have been covered by these patents.

 

Both companies exchanged upfront signing fees.

 

For further information, see the company statement.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.